Published in Front Psychiatry on October 14, 2013
Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur Child Adolesc Psychiatry (2014) 0.92
Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations. Philos Ethics Humanit Med (2014) 0.82
Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment. Ann Gen Psychiatry (2014) 0.82
Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction. Neuropsychopharmacology (2014) 0.81
Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophr Res (2014) 0.80
mHealth App for Cannabis Users: Satisfaction and Perceived Usefulness. Front Psychiatry (2015) 0.76
Cannabis Use and Dependence among French Schizophrenic Inpatients. Front Psychiatry (2014) 0.76
Clearing the smokescreen: the current evidence on cannabis use. Front Psychiatry (2015) 0.75
Adverse effects of marijuana use. Linacre Q (2016) 0.75
A critical assessment of the equal-environment assumption of the twin method for schizophrenia. Front Psychiatry (2015) 0.75
Toward the Identification of a Specific Psychopathology of Substance Use Disorders. Front Psychiatry (2017) 0.75
THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med (1965) 40.52
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A (2001) 9.42
Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry (1987) 8.81
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry (2005) 5.57
Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry (2005) 4.85
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A (1998) 3.99
What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol (1991) 3.62
The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med (2007) 3.45
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (2002) 3.06
Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction (2004) 2.97
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (2004) 2.93
Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol (2002) 2.80
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry (2008) 2.20
Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry (1999) 2.09
Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry (1994) 2.06
Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav (2005) 2.05
Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry (2011) 2.04
Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology (2003) 1.97
Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry (2008) 1.95
Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest (2005) 1.94
Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc (2003) 1.91
The environment and schizophrenia: the role of cannabis use. Schizophr Bull (2005) 1.90
The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci (2007) 1.68
Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol (2004) 1.67
Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med (2003) 1.67
Behavioural sensitization to daily life stress in psychosis. Psychol Med (2005) 1.58
Substance abuse and the onset of schizophrenia. Biol Psychiatry (1996) 1.55
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry (2008) 1.53
The association between early cannabis use and psychotic-like experiences in a community adolescent sample. Schizophr Res (2009) 1.46
Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry (1994) 1.39
Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry (2000) 1.36
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull (2010) 1.32
Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry (2010) 1.32
An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology (2006) 1.29
Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol (2008) 1.28
Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull (2008) 1.27
Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry (2006) 1.25
Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry (2006) 1.24
Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol (2004) 1.22
Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev (2006) 1.21
The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev (2000) 1.20
Gender-specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on cognitive function in children. Am J Psychiatry (2007) 1.20
Endophenotypes in schizophrenia: a selective review. Schizophr Res (2009) 1.19
Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry (2007) 1.19
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci (2007) 1.18
Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res (2005) 1.15
How antipsychotics become anti-"psychotic"--from dopamine to salience to psychosis. Trends Pharmacol Sci (2004) 1.15
Is active psychosis neurotoxic? Schizophr Bull (2006) 1.14
Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.11
Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci (2000) 1.09
Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull (2007) 1.08
The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res (2011) 1.08
Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res (1995) 1.06
Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci (2003) 1.04
Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord (2005) 1.00
Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry (2010) 1.00
The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) (2009) 0.99
Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett (2004) 0.99
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res (2007) 0.98
Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res (2004) 0.97
Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res (2009) 0.95
Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res (2008) 0.93
The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatr Scand (2008) 0.93
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry (2007) 0.93
Cannabis use and cognition in schizophrenia. Front Hum Neurosci (2009) 0.91
The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res (2007) 0.90
Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol (2010) 0.89
Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother (2008) 0.89
Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol (2003) 0.88
The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci (2002) 0.88
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci (2012) 0.88
Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex (2009) 0.87
Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res (2010) 0.86
Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr Bull (2013) 0.86
Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res (2004) 0.84
Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des (2012) 0.84
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des (2012) 0.84
Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des (2012) 0.82
Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophr Res (2008) 0.81
Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharm Des (2012) 0.81
Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res (2010) 0.80
Childhood psychological trauma and psychosis. Psychol Med (2008) 0.79
Cannabis use predicts shorter duration of untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study. Afr J Psychiatry (Johannesbg) (2010) 0.78
Increased gray matter density in patients with schizophrenia and cannabis use: a voxel-based morphometric study using DARTEL. Schizophr Res (2012) 0.77